Condition
Location

191 Clinical Trials near Tullahoma, TN

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Image of trial facility.

Inclisiran for Cardiovascular Disease Prevention

Tullahoma, Tennessee
This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 79
Sex:All
14013 Participants Needed
Image of trial facility.

Omecamtiv Mecarbil for Heart Failure

Tullahoma, Tennessee
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 85
Sex:All
1800 Participants Needed
Image of trial facility.

Pegozafermin for High Triglycerides

Tullahoma, Tennessee
This trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:22+
Sex:All
360 Participants Needed
Image of trial facility.

Orforglipron for Type 2 Diabetes and Obesity

Tullahoma, Tennessee
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
2749 Participants Needed
Image of trial facility.

Semaglutide for Childhood Obesity

Tullahoma, Tennessee
This trial will test if semaglutide helps children and teenagers lose weight. Participants will receive regular injections of semaglutide and will also get advice on healthy eating and physical activity. The study aims to see if semaglutide can help this age group manage their weight better.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 18
Sex:All
210 Participants Needed
Image of trial facility.

Linaclotide for Pediatric Constipation

Tullahoma, Tennessee
Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility. Currently, there are no pharmacological therapies approved for the treatment of FC. This study will assess adverse events and change in disease activity with linaclotide therapy in participants with FC. Linaclotide is an approved drug being developed for the treatment of FC in pediatric patients, ages 2 to 5, who meet modified Rome IV criteria for childhood FC. In Part 1 of this study, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. All participants in Part 2 will receive linaclotide. Approximately 116 participants aged 2 to 5 years with FC will be enrolled in this study at around 45 sites worldwide. Participants will receive daily doses of oral Linaclotide capsules or matching placebo for 12 weeks in Part 1 of the study. In Part 2, the open label long-term safety extension, participants with FC who completed study intervention in Part 1 of Study M21-572 or the Phase 2 Study LIN-MD-67 will receive linaclotide for 24 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2 - 5
Sex:All
123 Participants Needed
Image of trial facility.

Olpasiran for Cardiovascular Disease

Tullahoma, Tennessee
This trial is testing olpasiran, a medication that may reduce heart risks, in patients with heart disease and high levels of a specific type of fat called Lipoprotein(a). By lowering this fat, olpasiran aims to prevent heart attacks and other serious heart problems. Inclisiran is another emerging drug targeting LDL cholesterol, similar to olpasiran's focus on reducing lipoprotein(a).
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 85
Sex:All
7297 Participants Needed
Image of trial facility.

Inclisiran for Cardiovascular Disease

Tullahoma, Tennessee
This trial is testing inclisiran, an injectable drug, on people with heart disease who are already on strong cholesterol-lowering medications. The goal is to see if inclisiran can further reduce the risk of heart attacks and strokes by lowering bad cholesterol levels. Participants will receive the injection periodically. Inclisiran works by significantly reducing bad cholesterol levels.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
17004 Participants Needed
Image of trial facility.

Fixed Dose Triple vs Dual Combination for COPD

Tullahoma, Tennessee
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:Male
3433 Participants Needed
Image of trial facility.

Pentavalent Meningococcal Vaccine for Meningococcal Disease

Tullahoma, Tennessee
This trial is testing a new vaccine that protects against five types of meningococcal bacteria in adults and adolescents. The vaccine helps the body learn to fight off these bacteria.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:10 - 25
Sex:All
1220 Participants Needed
Image of trial facility.

BMS-986435 for Heart Failure

Tullahoma, Tennessee
This trial is testing a new drug called BMS-986435/MYK-224 in people with a specific type of heart failure (HFpEF). The goal is to see if the drug is safe and if it can help improve heart function and reduce symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 90
Sex:All
198 Participants Needed
Image of trial facility.

RTA 901 for Diabetic Neuropathy

Tullahoma, Tennessee
This trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
384 Participants Needed
Image of trial facility.

LY3556050 for Diabetic Peripheral Neuropathic Pain

Tullahoma, Tennessee
This trial is testing a new drug called LY3556050 to see if it can help reduce nerve pain in people with diabetes. The study will last several months and will compare the effects of LY3556050 to another treatment. The goal is to determine if LY3556050 is safe and effective for treating diabetic nerve pain.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
410 Participants Needed
Image of trial facility.

Drug-Coated Balloon Angioplasty for Peripheral Arterial Disease

Tullahoma, Tennessee
This study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
300 Participants Needed
Image of trial facility.

mRNA-0184 for Heart Failure

Tullahoma, Tennessee
The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses at escalating dose levels of mRNA-0184.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
98 Participants Needed
Image of trial facility.

SELUTION SLR™ for Peripheral Arterial Disease

Tullahoma, Tennessee
This trial tests a special balloon called SELUTION SLR™ DEB 014 for patients with severe leg artery blockages. The balloon helps open the artery and releases medicine to prevent it from getting blocked again.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
376 Participants Needed
Image of trial facility.

Cancer Vaccine for Lung Cancer

Shelbyville, Tennessee
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
363 Participants Needed
Image of trial facility.

ARV-471 for Breast Cancer

Shelbyville, Tennessee
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
624 Participants Needed
Image of trial facility.

BLI5100 for Erosive Esophagitis

Shelbyville, Tennessee
This trial tests BLI5100, an oral medication, in patients with Erosive Esophagitis (EE). It aims to see if BLI5100 can heal the esophagus and maintain its healing.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
1250 Participants Needed
Image of trial facility.

Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Breast Cancer

Shelbyville, Tennessee
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
443 Participants Needed
Image of trial facility.

Lorlatinib vs Crizotinib for Non-Small Cell Lung Cancer

Shelbyville, Tennessee
A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
296 Participants Needed
Image of trial facility.

Sacituzumab Govitecan for Triple-Negative Breast Cancer

Shelbyville, Tennessee
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
540 Participants Needed
Image of trial facility.

Adagrasib + Pembrolizumab for Lung Cancer

Shelbyville, Tennessee
This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18+
Sex:All
806 Participants Needed
Image of trial facility.

Nab-sirolimus for Cancer

Shelbyville, Tennessee
This trial is testing a new drug on adults and adolescents with certain genetic changes in their tumors. These changes make their cancer hard to treat with standard methods. The drug works by blocking a pathway that helps the cancer grow, aiming to slow down or stop tumor growth. The drug has been studied for its effectiveness and safety in various types of cancer.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:12+
Sex:All
120 Participants Needed
Image of trial facility.

Encorafenib + Binimetinib for Non-Small Cell Lung Cancer

Shelbyville, Tennessee
This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
98 Participants Needed
Image of trial facility.

TAK-279 for Psoriasis

Murfreesboro, Tennessee
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
1300 Participants Needed
Image of trial facility.

VDPHL01 for Male Pattern Baldness

Murfreesboro, Tennessee
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). The first 7 visits will be part of the placebo-controlled period. The next 3 visits will be part of the treatment extension phase. All subjects will receive active drug in the treatment extension phase.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65
Sex:Male
480 Participants Needed
Image of trial facility.

Dapirolizumab Pegol for Lupus

Murfreesboro, Tennessee
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:16+
Sex:All
450 Participants Needed
Image of trial facility.

Ixekizumab + Tirzepatide for Psoriatic Arthritis

Murfreesboro, Tennessee
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 80
Sex:All
250 Participants Needed
Image of trial facility.

Ixekizumab + Tirzepatide for Psoriasis

Murfreesboro, Tennessee
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
250 Participants Needed
Page 1 of 7+

Frequently Asked Questions

How much do clinical trials in Tullahoma, TN pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Tullahoma, TN work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Tullahoma, TN 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Tullahoma, TN is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Tullahoma, TN several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Tullahoma, TN ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Tullahoma, TN ?

Most recently, we added cAD3-Sudan Vaccine for Sudan Ebolavirus, BMS-986368 for Alzheimer's Disease and RSVpreF + Shingles Vaccine for Respiratory Syncytial Virus to the Power online platform.

Other People Viewed

tDCS + Speech-Language Therapy for Aphasia (AphasiatDCS Trial)

JSP191 for Myelodysplastic Syndrome

AG-01 Antibody Therapy for Advanced Cancers

Standard vs. Accelerated Corneal Crosslinking for Keratoconus

Focal Laser Ablation for Prostate Cancer

Glucose Tolerance Test + Continuous Glucose Monitoring for Postpartum High Blood Sugar

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Sacubitril-Valsartan for Heart Failure in HIV

Gene Therapy for Duchenne Muscular Dystrophy

Abatacept Infusion for COVID-19

Psilocybin Microdosing for Depression

Maraviroc + Exercise for Stroke Recovery (CAMAROS Trial)

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top